Table 5 24-h urinary glucose and electrolyte excretion, after single-dose administration of remogliflozin etabonate (20–1000 mg) in healthy volunteers (n = 8 per remogliflozin etabonate group and n = 10 for placebo) and subjects with T2DM (n = 6)

6.5 (18.6)^a

67.1 (17.9)

96.7 (17.1)^b

168 (49.4)^b

223 (49.5)

304 (137)

0.9 (2.4)^a

9.0 (2.2)

12.7 (3.7)^b

25.5 (7.8)^b

34.2 (5.0)

26.4 (11.7)

162 (49.4)^a

148 (64.0)

212 (67.6)^b

176 (38.7)^b

143 (55.0)

207 (62.9)

141 (39.8)^a

136 (56.6)

189 (51.4)^b

179 (49.6)^b

126 (55)

201 (61.5)

62.2 (15.7)^a

66.6 (27.7)

75.2 (21.3)^b

59.7 (20.3)^b

55.8 (17.2)

89.1 (24.7)

40.4 (62.4)^c

384 (210)

642 (256)

2.3 (3.6)^c

15.9 (5.9)^c

21.6 (9.1)

196 (39.2)^c

173 (35.5)^c

301 (128)

181 (48.3)^c

168 (23.9)^c

287 (147)

71.7 (12.1)^c

65.8 (4.5)^c

108 (65.8)